Consequently, we run the appropriate TOST test for each data set based
on the rejection or acceptance of variance and distribution from the p values in Table \ref{stats-results}. We derive several conclusions from each
respective TOST test on each data set.
- We find that BPD falls within the set bounds with a p value of
0.0076. Assuming a \(\mathrm{\propto}\) = 0.05 cutoff,
this is well beneath the required value, suggesting that this
correlation is not due to random chance.
- However, the SCZ data set, tested with equal variance, obtains a p value of 0.13, which is greater than the predefined \(\mathrm{\propto}\). This suggests that such a result may be due to
random chance.
Therefore, we find that AKAP11 has a strong correlation with the
diagnosis of BPD and a slight correlation to SCZ. This is because we
find a correlation for both SCZ and BPD when the variants are analyzed
genetically using amino acids, but a statistically insignificant effect
on SCZ when tested against the Canadian population. In both cases, we
reject the null hypothesis that AKAP11 has no effect on the
diagnosis of SCZ and BPD.